Short answer
Editas Medicine, Inc. (EDIT) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $12M (up 232.3% year over year) with net income of −$18M.
Q2 2026 key financials · XBRL
- Revenue
- $12M
- +232.3% YoY · +320.0% QoQ
- Net income
- −$18M
- +65.8% YoY · +27.0% QoQ
- Operating margin
- -156.0%
- EPS (diluted)
- −$0.14
- +77.4% YoY · +46.2% QoQ
Source: XBRL data from the Editas Medicine, Inc. (EDIT) Q2 2026 10-Q on SEC EDGAR. USD.
Editas Medicine, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Net losses $43.2M for six months ended June 30, 2026 vs $129.3M in 2025
- Best-performing program EDIT-401; approximately 90%+ LDL-C reduction in preclinical NHP studies
- EDIT-401 Phase 1/2 trial targeted for 2026; topline Part 1 data expected in 2027
Risk Factors
- Patent priority risk: PTAB reaffirmed Broad’s priority on March 26, 2026; CVC appealed to the CAFC
- Regulatory risk: five parallel PTAB interferences create potential loss, narrowing, or invalidation of CRISPR/Cas9 rights
- Legal risk: ToolGen–Broad interference suspension lifted after the March 2026 remand decision
- Operational risk: adverse patent outcomes could force cessation of product-candidate development, manufacturing, or commercialization
- International IP risk: European Patent Office revoked certain in-licensed Broad patents and amended others pending appeal
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Editas Medicine, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.